Andrada Mining acquisition elevates the miner to emerging mid-tier status. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPureTech Regulatory News (PRTC)

Share Price Information for PureTech (PRTC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 183.00
Bid: 183.00
Ask: 184.00
Change: -4.80 (-2.56%)
Spread: 1.00 (0.546%)
Open: 190.00
High: 190.00
Low: 181.80
Prev. Close: 187.80
PRTC Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

6 Jul 2020 07:00

RNS Number : 0566S
PureTech Health PLC
06 July 2020
 

TR-1: Standard form for notification of major holdings

 

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii:

Puretech Health PLC

1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)

Non-UK issuer

2. Reason for the notification (please mark the appropriate box or boxes with an "X")

An acquisition or disposal of voting rights

An acquisition or disposal of financial instruments

An event changing the breakdown of voting rights

Other (please specify)iii: As of 1 July 2020, Merian Global Investors Limited is owned by Jupiter Fund Management Plc. Any positions in Merian Global Investors Limited are transferred to Jupiter Fund Management Plc.

The disclosure also highlights the full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entity detailed within Section 9, following this change of ownership.

X

3. Details of person subject to the notification obligationiv

Name

Jupiter Fund Management Plc

City and country of registered office (if applicable)

4. Full name of shareholder(s) (if different from 3.)v

Name

Northern Trust

City and country of registered office (if applicable)

5. Date on which the threshold was crossed or reachedvi:

01/07/2020

6. Date on which issuer notified (DD/MM/YYYY):

03/07/2020

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8. A)

% of voting rights through financial instruments(total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights of issuervii

Resulting situation on the date on which threshold was crossed or reached

5.53%

0%

5.53%

285,512,461

Position of previous notification (if

applicable)

N/A

N/A

N/A

 

8. Notified details of the resulting situation on the date on which the threshold was crossed or reachedviii

A: Voting rights attached to shares

Class/type ofshares

ISIN code (if possible)

Number of voting rightsix

% of voting rights

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

GB00BY2Z0H74

N/A

15,799,957

 

N/A

5.53%

SUBTOTAL 8. A

15,799,957

 

5.53%

 

 

B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))

Type of financial instrument

Expirationdatex

Exercise/Conversion Periodxi

Number of voting rights that may be acquired if the instrument is

exercised/converted.

% of voting rights

N/A

N/A

N/A

N/A

N/A

SUBTOTAL 8. B 1

N/A

N/A

 

 

B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))

Type of financial instrument

Expirationdatex

Exercise/Conversion Period xi

Physical or cash

settlementxii

Number of voting rights

% of voting rights

N/A

N/A

N/A

N/A

N/A

N/A

SUBTOTAL 8.B.2

N/A

N/A

 

 

 

 

 

 

9. Information in relation to the person subject to the notification obligation (please mark the

applicable box with an "X")

Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuerxiii

Full chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entityxiv (please add additional rows as necessary)

X

Name

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

Jupiter Fund Management Plc

Jupiter Fund Management Group Limited

Jupiter Asset Management Group Limited

Knightsbridge Asset Management Limited

Jupiter Investment Management Group Limited

Jupiter Asset Management Limited

5.53%

0%

5.53%

Jupiter Fund Management Plc

Merian Global Investors Limited

Merian Global Investors (Jersey) Limited

Merian Global Investors (Finance) Limited

Merian Global Investors Holdings Limited

Merian Global Investors (UK) Limited

 

 

 

 

 

10. In case of proxy voting, please identify:

Name of the proxy holder

The number and % of voting rights held

N/A

The date until which the voting rights will be held

N/A

11. Additional informationxvi

Contact : Claire Rodway

 

Telephone Number : 0203 817 1441

 

Place of completion

London, UK

Date of completion

3rd July 2020

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
HOLRAMLTMTJMBRM
Date   Source Headline
4th Oct 20194:35 pmRNSPrice Monitoring Extension
4th Oct 201912:07 pmRNSSecond Price Monitoring Extn
4th Oct 201912:02 pmRNSPrice Monitoring Extension
2nd Oct 20197:00 amRNSMinority Stake Acquisition & PDMR Notification
1st Oct 20194:40 pmRNSSecond Price Monitoring Extn
1st Oct 20194:35 pmRNSPrice Monitoring Extension
1st Oct 20191:15 pmRNSVor Appoints Senior Cell & Gene Therapy Leaders
1st Oct 20197:00 amRNSTotal Voting Rights
23rd Sep 20194:40 pmRNSSecond Price Monitoring Extn
23rd Sep 20194:35 pmRNSPrice Monitoring Extension
23rd Sep 201912:07 pmRNSSecond Price Monitoring Extn
23rd Sep 201912:02 pmRNSPrice Monitoring Extension
23rd Sep 20197:00 amRNSVedanta Expands Series C with $62.1M Total Raised
16th Sep 20194:40 pmRNSSecond Price Monitoring Extn
16th Sep 20194:35 pmRNSPrice Monitoring Extension
9th Sep 201912:07 pmRNSSecond Price Monitoring Extn
9th Sep 201912:02 pmRNSPrice Monitoring Extension
9th Sep 20197:00 amRNSPureTech Announces Board Change
6th Sep 20194:41 pmRNSSecond Price Monitoring Extn
6th Sep 20194:35 pmRNSPrice Monitoring Extension
4th Sep 201912:07 pmRNSSecond Price Monitoring Extn
4th Sep 201912:02 pmRNSPrice Monitoring Extension
27th Aug 20197:00 amRNSPureTech Health plc Half-Year Report
20th Aug 20197:00 amRNSNotice of Results
19th Aug 201912:02 pmRNSPrice Monitoring Extension
14th Aug 20195:30 pmRNSBTG
7th Aug 20191:40 pmRNSVor Names Biotech Vet Robert Ang President & CEO
1st Aug 20197:00 amRNSTotal Voting Rights
31st Jul 20191:40 pmRNSVor Biopharma Adds R&D Leader Bill Lundberg to BOD
17th Jul 20197:00 amRNSPRTC Acquires Clinical Stage Asset for Lymphedema
11th Jul 20197:00 amRNSPotential US Listing of PureTech Health on Nasdaq
9th Jul 20197:00 amRNSPRTC Immuno-Oncology Programme Granted US Patent
3rd Jul 20197:00 amRNSPRTC's Karuna closes IPO, gross proceeds $102.6M
1st Jul 20197:00 amRNSFirst Patient in Vedanta Food Allergy Study
28th Jun 20197:00 amRNSPureTech's Karuna successfully lists on NASDAQ
20th Jun 20197:00 amRNSPureTech Announces New Corporate HQ/Internal Labs
13th Jun 20197:00 amRNSFollica Positive Interim Data & Plans for Pivotal
3rd Jun 20197:00 amRNSPRTC's Karuna Files Public S1 for NASDAQ IPO
30th May 20197:05 amRNSPRTC to Present at Jefferies US Conference
30th May 20197:00 amRNSResult of AGM
29th May 20197:00 amRNSVor Publishes POC Study in Scientific Journal
21st May 20197:00 amRNSVedanta Presents Expanded Data from Successful Ph1
20th May 20197:00 amRNSPromising Gelesis Data in Chronic Constipation
14th May 20197:00 amRNSGelesis & Vedanta Data at Digestive Disease Week
13th May 20197:00 amRNSVedanta Grows Series C Financing to $45.5 Million
7th May 20197:00 amRNSVedanta Prevails in Important EU Patent Opposition
26th Apr 20197:15 amRNSPRTC's Karuna Files IPO Registration Statement
25th Apr 20197:00 amRNSGelesis Gets $10.6M Grant to Support Manufacturing
24th Apr 20197:00 amRNSFinal Results
17th Apr 20197:00 amRNSBoehringer Ingelheim & PRTC Immuno-oncology Collab

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.